This company listing is no longer active
LCAR Stock Overview
Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Lescarden Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.000001 |
| 52 Week High | US$0.0001 |
| 52 Week Low | US$0.000001 |
| Beta | 0 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | -99.96% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
No updates
Recent updates
No updates
Shareholder Returns
| LCAR | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 0% | 1.9% | 0.8% |
| 1Y | n/a | 22.5% | 26.3% |
Return vs Industry: Insufficient data to determine how LCAR performed against the US Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how LCAR performed against the US Market.
Price Volatility
| LCAR volatility | |
|---|---|
| LCAR Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: LCAR has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine LCAR's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1960 | n/a | William Luther | https://www.lescarden.com |
Lescarden Inc. researches, tests, develops, and sells medications for the control and cure of various diseases in the United States, Europe, and South Korea. Its lead product is Catrix Wound Dressing for the management of chronic lesions and burns, as well as for non-healing wounds, including decubitus ulcers, venous stasis ulcers, and diabetic ulcers. The company also offers a line of Catrix-based wound and skin care products for the plastic surgery, dermatology, and medical spa markets.
Lescarden Inc. Fundamentals Summary
| LCAR fundamental statistics | |
|---|---|
| Market cap | US$63.00 |
| Earnings (TTM) | -US$8.36k |
| Revenue (TTM) | US$424.01k |
0.0x
P/S Ratio0.0x
P/E RatioIs LCAR overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| LCAR income statement (TTM) | |
|---|---|
| Revenue | US$424.01k |
| Cost of Revenue | US$174.02k |
| Gross Profit | US$249.99k |
| Other Expenses | US$258.35k |
| Earnings | -US$8.36k |
Last Reported Earnings
Feb 28, 2017
Next Earnings Date
n/a
| Earnings per share (EPS) | 0 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0.0% |
How did LCAR perform over the long term?
See historical performance and comparison